Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neurogeriatrics-a vision for improved care and research for geriatric patients with predominating neurological disabilities.
Jacobs AH, Emmert K, Baron R, Bartsch T, Bauer J, Becker C, Berg D, Bergmann P, Boetzel K, Bollheimer C, Deuschl G, Djukic M, Drey M, Durwen H, Ebersbach G, Elshehabi M, Geritz J, Gisinger C, Guennewig T, Hauptmann B, Heppner HJ, Hobert MA, Hofmann W, Huellemann P, Jahn K, Klucken J, Kurth R, Lindner R, Lingor P, Lukas A, Maetzold S, Mokrusch T, Mollenhauer B, Nau R, Plate A, Polidori MC, Prell T, Schellinger P, Spira D, Stephani U, Studt S, Trenkwalder C, Unger HL, Urban P, von Arnim CAF, Warnecke T, Weiss M, Wiedemann A, Wirth R, Witt K, Dodel R, Maetzler W. Jacobs AH, et al. Among authors: kurth r. Z Gerontol Geriatr. 2020 Jul;53(4):340-346. doi: 10.1007/s00391-020-01734-1. Epub 2020 May 19. Z Gerontol Geriatr. 2020. PMID: 32430766 Free PMC article. Review.
Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn-study.
Geritz J, Maetzold S, Steffen M, Pilotto A, Corrà MF, Moscovich M, Rizzetti MC, Borroni B, Padovani A, Alpes A, Bang C, Barcellos I, Baron R, Bartsch T, Becktepe JS, Berg D, Bergeest LM, Bergmann P, Bouça-Machado R, Drey M, Elshehabi M, Farahmandi S, Ferreira JJ, Franke A, Friederich A, Geisler C, Hüllemann P, Gierthmühlen J, Granert O, Heinzel S, Heller MK, Hobert MA, Hofmann M, Jemlich B, Kerkmann L, Knüpfer S, Krause K, Kress M, Krupp S, Kudelka J, Kuhlenbäumer G, Kurth R, Leypoldt F, Maetzler C, Maia LF, Moewius A, Neumann P, Niemann K, Ortlieb CT, Paschen S, Pham MH, Puehler T, Radloff F, Riedel C, Rogalski M, Sablowsky S, Schanz EM, Schebesta L, Schicketmüller A, Studt S, Thieves M, Tönges L, Ullrich S, Urban PP, Vila-Chã N, Wiegard A, Warmerdam E, Warnecke T, Weiss M, Welzel J, Hansen C, Maetzler W. Geritz J, et al. Among authors: kurth r. BMC Geriatr. 2020 Feb 6;20(1):45. doi: 10.1186/s12877-020-1445-z. BMC Geriatr. 2020. PMID: 32028945 Free PMC article.
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein Disease.
Brown EG, Chahine LM, Siderowf A, Gochanour C, Kurth R, Marshall MJ, Caspell-Garcia C, Brumm MC, Stanley CE Jr, Korell M, McMahon B, Kuhl M, Fabrizio K, Heathers L, Concha-Marambio L, Soto C, Chowdhury S, Coffey CS, Foroud TM, Simuni T, Marek K, Tanner CM; Parkinson Progression Marker Initiative. Brown EG, et al. Among authors: kurth r. Ann Neurol. 2024 Dec 24. doi: 10.1002/ana.27158. Online ahead of print. Ann Neurol. 2024. PMID: 39719857
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmia.
Weintraub D, Nair AR, Kurth R, Brumm MC, York MK, Dobkin R, Marek K, Tanner C, Simuni T, Siderowf A, Galasko D, Chahine LM, Coffey C, Merchant K, Poston KL, Foroud T, Mollenhauer B, Brown EG, Kieburtz K, Frasier M, Sherer T, Chowdhury S, Alcalay RN, Videnovic A; Parkinson’s Progression Markers Initiative. Weintraub D, et al. Among authors: kurth r. medRxiv [Preprint]. 2024 Dec 13:2024.12.12.24318917. doi: 10.1101/2024.12.12.24318917. medRxiv. 2024. PMID: 39711699 Free PMC article. Preprint.
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Miyazaki I, et al. Among authors: kurth ri. Nat Cancer. 2023 Oct;4(10):1526. doi: 10.1038/s43018-023-00663-3. Nat Cancer. 2023. PMID: 37814012 Free PMC article. No abstract available.
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Miyazaki I, et al. Among authors: kurth ri. Nat Cancer. 2023 Sep;4(9):1345-1361. doi: 10.1038/s43018-023-00630-y. Epub 2023 Sep 21. Nat Cancer. 2023. PMID: 37743366 Free PMC article.
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C; Parkinson's Progression Markers Initiative. Siderowf A, et al. Among authors: kurth r. Lancet Neurol. 2023 May;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6. Lancet Neurol. 2023. PMID: 37059509 Free PMC article.
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.
Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, Marek K; Parkinson’s Progression Marker Initiative Authors. Simuni T, et al. NPJ Parkinsons Dis. 2022 Oct 22;8(1):140. doi: 10.1038/s41531-022-00404-w. NPJ Parkinsons Dis. 2022. PMID: 36273008 Free PMC article.
318 results